Tvm Life Science Ventures Vi Gmbh & Co Kg Insider of Acer Therapeutics Inc. (ACER) Just Purchased Shares In It; Senzar Asset Management Has Cut Anthem (ANTM) Holding By $3.34 Million

Senzar Asset Management Llc decreased Anthem Inc (ANTM) stake by 12.23% reported in 2017Q3 SEC filing. Senzar Asset Management Llc sold 17,650 shares as Anthem Inc (ANTM)’s stock rose 10.08%. The Senzar Asset Management Llc holds 126,700 shares with $24.06M value, down from 144,350 last quarter. Anthem Inc now has $61.20 billion valuation. The stock increased 1.42% or $3.335 during the last trading session, reaching $238.335. About 867,431 shares traded. Anthem, Inc. (NYSE:ANTM) has risen 31.86% since January 12, 2017 and is uptrending. It has outperformed by 15.16% the S&P500.

The insider of Acer Therapeutics Inc, Tvm Life Science Ventures Vi Gmbh & Co Kg is in the stock market news today. It was published in a legal report filled by Tvm Life Science Ventures Vi Gmbh & Co Kg and submitted to the DC-based SEC on January 12, 2018, the insider purchased 333,333 shares from the stock exchange listed company worth near $4.00 million U.S. Dollars. The shares average price was $12.0. Due to the significance of this transaction, it will not stay unnoticed. Tvm Life Science Ventures Vi Gmbh & Co Kg owns 31.98% of the -company’s market cap with a total of 2.40 million shares.

Among 24 analysts covering Anthem Inc (NYSE:ANTM), 13 have Buy rating, 0 Sell and 11 Hold. Therefore 54% are positive. Anthem Inc had 63 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Buy” rating by RBC Capital Markets given on Tuesday, May 30. The company was maintained on Wednesday, October 25 by Jefferies. The rating was maintained by RBC Capital Markets with “Buy” on Monday, October 2. The rating was initiated by Cleveland on Friday, April 8 with “Buy”. Cantor Fitzgerald maintained Anthem, Inc. (NYSE:ANTM) on Monday, November 6 with “Buy” rating. RBC Capital Markets maintained the stock with “Outperform” rating in Thursday, July 30 report. On Thursday, January 28 the stock rating was maintained by RBC Capital Markets with “Outperform”. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, February 2. The firm has “Neutral” rating given on Wednesday, January 4 by Piper Jaffray. Sterne Agee CRT downgraded the shares of ANTM in report on Tuesday, May 24 to “Neutral” rating.

Analysts await Anthem, Inc. (NYSE:ANTM) to report earnings on February, 7. They expect $1.25 EPS, down 28.98% or $0.51 from last year’s $1.76 per share. ANTM’s profit will be $320.95 million for 47.67 P/E if the $1.25 EPS becomes a reality. After $2.65 actual EPS reported by Anthem, Inc. for the previous quarter, Wall Street now forecasts -52.83% negative EPS growth.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company has market cap of $138.07 million. The firm offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease . It currently has negative earnings. It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD).

The stock decreased 7.88% or $1.57 during the last trading session, reaching $18.42. About 58,991 shares traded or 130.42% up from the average. Acer Therapeutics Inc. (NASDAQ:ACER) has 0.00% since January 12, 2017 and is . It has underperformed by 16.70% the S&P500.